Daily Stock Analysis, EIRL, CELLADON CORPORATION - COMMON STOCK, priceseries

CELLADON CORPORATION - COMMON STOCK. Daily Stock Analysis
Stock Information
Open
54.03
Close
53.57
High
54.12
Low
53.57
Previous Close
53.46
Daily Price Gain
0.11
YTD High
59.01
YTD High Date
Jan 12, 2022
YTD Low
52.85
YTD Low Date
Jan 24, 2022
YTD Price Change
-3.75
YTD Gain
-6.54%
52 Week High
62.15
52 Week High Date
Sep 7, 2021
52 Week Low
47.76
52 Week Low Date
Jan 29, 2021
52 Week Price Change
4.82
52 Week Gain
9.88%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Oct 11. 2019
40.92
Nov 20. 2019
43.06
28 Trading Days
5.24%
Link
LONG
May 22. 2020
34.08
Jun 9. 2020
37.11
11 Trading Days
8.91%
Link
LONG
Nov 3. 2020
42.51
Dec 11. 2020
48.41
27 Trading Days
13.88%
Link
Company Information
Stock Symbol
EIRL
Exchange
NasdaqGM
Company URL
http://www.eigerbio.com
Company Phone
650-279-9845
CEO
David A. Cory
Headquarters
California
Business Address
350 CAMBRIDGE AVE, SUITE 350, PALO ALTO, CA 94306
Sector
-
Industry Category
-
Industry Group
-
CIK
0001305253
About

Eiger BioPharmaceuticals, Inc. is a clinical-stage company, which engages in the research, development, and commercialization of biopharmaceutical products. It focuses on product candidates for the treatment of orphan diseases such as Sarasar, Pegylated Interferon Lambda, Exendin 9-39, and Ubenimex. The company was founded by David A. Cory on November 6, 2008 and is headquartered in Palo Alto, CA.

Description

Eiger BioPharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on providing various products for the treatment of orphan diseases in the United States. It portfolio of products include Sarasar, an indication for the hepatitis delta virus infection; Exendin, which is used for the treatment of hypoglycemia associated with bariatric surgery; and Bestatin that is used for the treatment of pulmonary arterial hypertension and lymphedema, which are under Phase II clinical trials. The company was founded in 2008 and is headquartered in Palo Alto, California.